ArticleAbdominal radiology (New York)2026
[
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis study aimed to systematically compare the diagnostic performance of gallium-68–labeled fibroblast activation protein inhibitor-04 ([68Ga]-FAPI-04) and fluorine-18 fluorodeoxyglucose ([18F]-FDG) for gastric cancer staging using positron emission tomography combined with computed tomography (PET/CT) and positron emission tomography combined with magnetic resonance imaging (PET/MR).
methodsIn this single-center retrospective study, 35 patients with pathologically confirmed gastric cancer underwent sequential imaging with [68Ga]-FAPI-04 (PET/CT and PET/MR) and [18F]-FDG (PET/CT and/or PET/MR) within 48 h. Diagnostic performance for primary tumors, lymph node metastases, and distant metastases was evaluated against histopathological results or clinical follow-up. Semi-quantitative parameters, including maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR), were compared across tracers and modalities.
results[68Ga]-FAPI-04 exhibited significantly higher SUVmax and TBR than [18F]-FDG in primary tumors, lymph node and peritoneal metastases. Notably, [68Ga]-FAPI-04 maintained consistently high uptake in signet-ring cell carcinoma, a subtype where [18F]-FDG uptake was significantly lower. Both [68Ga]-FAPI-04 PET/CT and PET/MR significantly outperformed all [18F]-FDG-based modalities for metastasis detection, with no statistically significant difference in overall diagnostic efficacy between the two [68Ga]-FAPI-04 platforms. [68Ga]-FAPI-04 PET/MR achieved 100% lesion-level sensitivity for peritoneal metastases, while PET/CT yielded higher absolute SUVmax values and PET/MR showed superior TBR.
conclusion[68Ga]-FAPI-04 outperforms [18F]-FDG in the detection of primary gastric cancer, regional lymph node metastases and peritoneal metastases, with consistently high tumor uptake in [18F]-FDG-insensitive histological subtypes including signet-ring cell carcinoma. [68Ga]-FAPI-04 PET/CT and PET/MR offer comparable overall diagnostic performance at the patient level, with no statistically significant differences observed between the two platforms and both modalities markedly improve the accuracy of gastric cancer staging.
Indexed as
Identifiers
42008172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.